Furthermore, we have successfully completed two clinical trials, affirming the efficacy and reliability of our product. These trials have substantiated Auto Train Brain as the sole patented solution worldwide that effectively improves the symptoms of dyslexia, a condition affecting 10% of the global population. This immense market potential further enhances the value and relevance of our offering.
In terms of performance, our product boasts an impressive effect size of 0.88, surpassing competitors such as Myndlift and chooseMuse. This exceptional effect size underscores the effectiveness and impact of Auto Train Brain, making it the leading choice for individuals seeking dyslexia symptom improvement.
One of our key advantages is the user-friendly nature of our product. Auto Train Brain can be conveniently used at home without the need for a neurofeedback expert, allowing for a seamless and accessible experience for our users. Moreover, our software is language-independent, transcending barriers and catering to a global audience.
I am thrilled to share that we are on the brink of securing a commitment from the Turkish government. This partnership will enable us to develop an EEG headset and establish a presence in 4,000 rehabilitation centers across Turkey. This monumental opportunity promises extensive growth and market penetration, further reinforcing our projected valuation.
Considering these remarkable achievements and prospects, we have conservatively estimated our valuation at an impressive 1 Billion USD. We believe in the potential of our product and eagerly anticipate the chance to showcase its value and impact.
I am delighted to present to you the extraordinary investments that have been made in our company, which showcase the immense faith and confidence in our groundbreaking dyslexia rehabilitation solution. Prepare to be inspired by the remarkable investments we have received:
DCP Investment: Through a DCP (Convertible Debt) arrangement, we secured a significant investment of 50,000 EUR. This partnership not only demonstrates the financial support we have garnered but also signifies the belief in our transformative approach to dyslexia rehabilitation.
Sabancı University Investment: We are honored to announce a substantial investment of 100,000 USD from Sabancı University. This prestigious partnership reinforces the recognition of our groundbreaking research and development efforts and further fuels our drive to revolutionize dyslexia rehabilitation.
TÜBİTAK 1512 Grant: Our exceptional work has been acknowledged through a prestigious grant of 50,000 USD from TÜBİTAK, the esteemed Scientific and Technological Research Council of Turkey. This grant serves as a testament to our innovative research and development endeavors, propelling us to new heights.
TÜBİTAK 1507 Grant: Additionally, we received another remarkable grant of 50,000 USD from TÜBİTAK through their esteemed 1507 Program. This endorsement solidifies our position as a leading innovator in the dyslexia rehabilitation field and empowers us to continue pushing boundaries.
TÜBİTAK ARDEB Grant: We are proud to have secured an esteemed ARDEB (Research Support Programs) grant of 50,000 USD from TÜBİTAK. This grant not only acknowledges our exceptional research efforts but also provides the resources necessary to advance our product and positively impact the lives of dyslexic individuals.
KOSGEB Support: In addition to the grants, we were fortunate to receive the support of 20,000 USD from KOSGEB (Small and Medium Enterprises Development Organization). This invaluable support has enabled us to expand our operations, reach a wider audience, and bring our innovative solution to those who need it most.
Gunet Eroğlu Investment: One of the most significant milestones in our journey is the substantial investment of 100,000 USD from me. As a mother of a dyslexic kid, it was my social responsibility to enhance the lives of dyslexic children in the world.
EMOTIV Partnership: We are thrilled to announce a strategic partnership with EMOTIV, a leading company in neurotechnology. This partnership includes an investment of 10,000 USD ( as headsets) along with a generous 30% discount on EMOTIV headsets. This collaboration further strengthens our technological capabilities and broadens our potential impact.
While we are humbled by the interest shown by other potential investors, we have prioritized securing patents to protect our intellectual property. Consequently, we regretfully could not accept additional investment requests until now.
These investments and our robust patent propel us forward with unwavering determination and unwavering focus. We are resolute in our commitment to advancing our product, positively impacting the lives of dyslexic individuals, and shaping a brighter future for all.
Moreover, I would like to express my heartfelt gratitude for the contributions of the doctors (MDs), academics, families, and children who participated in our clinical trials, all of whom have been an invaluable part of our team. Their selfless dedication and support have played a vital role in shaping our solution and driving it toward success. We are deeply grateful for their unwavering commitment to improving the lives of dyslexic individuals and their willingness to join us on this extraordinary journey. Their involvement and input have been instrumental in refining our product and ensuring its effectiveness. To each and every one of them, we extend our sincerest appreciation and admiration for their invaluable contributions to creating an effective solution for dyslexia rehabilitation.